Literature DB >> 23531638

Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer.

Sarah R Walker1, Michael Xiang1, David A Frank2.   

Abstract

The transcription factors STAT3 and STAT5 play important roles in the regulation of mammary gland function during pregnancy, lactation, and involution. Given that STAT3 and STAT5 regulate genes involved in proliferation and survival, it is not surprising that inappropriate activation of STAT3 and STAT5 occurs commonly in breast cancer. Although these proteins are structurally similar, they have divergent and opposing effects on gene expression and cellular phenotype. Notably, when STAT5 and STAT3 are activated simultaneously, STAT5 has a dominant effect, and leads to decreased proliferation and increased sensitivity to cell death. Similarly, in breast cancer, activation of both STAT5 and STAT3 is associated with longer patient survival than activation of STAT3 alone. Pharmacological inhibitors of STAT3 and STAT5 are being developed for cancer therapy, though understanding the activation state and functional interaction of STAT3 and STAT5 in a patient's tumor may be critical for the optimal use of this strategy.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Gene expression; Oncology; Signal transduction; Transcription factors

Mesh:

Substances:

Year:  2013        PMID: 23531638      PMCID: PMC3732813          DOI: 10.1016/j.mce.2013.03.010

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  70 in total

1.  Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation.

Authors:  Yongzhi Cui; Greg Riedlinger; Keiko Miyoshi; Wei Tang; Cuiling Li; Chu-Xia Deng; Gertraud W Robinson; Lothar Hennighausen
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

2.  The genes induced by signal transducer and activators of transcription (STAT)3 and STAT5 in mammary epithelial cells define the roles of these STATs in mammary development.

Authors:  Richard W E Clarkson; Marion P Boland; Ekaterini A Kritikou; Jennifer M Lee; Tom C Freeman; Paul G Tiffen; Christine J Watson
Journal:  Mol Endocrinol       Date:  2005-11-17

3.  A MGF/STAT5 binding site is necessary in the distal enhancer for high prolactin induction of transfected rabbit alpha s1-casein-CAT gene transcription.

Authors:  G Jolivet; C L'Hotte; S Pierre; N Tourkine; L M Houdebine
Journal:  FEBS Lett       Date:  1996-07-08       Impact factor: 4.124

4.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

5.  A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells.

Authors:  Hui Song; Renxiao Wang; Shaomeng Wang; Jiayuh Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

6.  Stat5a is mandatory for adult mammary gland development and lactogenesis.

Authors:  X Liu; G W Robinson; K U Wagner; L Garrett; A Wynshaw-Boris; L Hennighausen
Journal:  Genes Dev       Date:  1997-01-15       Impact factor: 11.361

7.  Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.

Authors:  Howard Y Chang; Dimitry S A Nuyten; Julie B Sneddon; Trevor Hastie; Robert Tibshirani; Therese Sørlie; Hongyue Dai; Yudong D He; Laura J van't Veer; Harry Bartelink; Matt van de Rijn; Patrick O Brown; Marc J van de Vijver
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-08       Impact factor: 11.205

8.  Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.

Authors:  Michelle A Blaskovich; Jiazhi Sun; Alan Cantor; James Turkson; Richard Jove; Saïd M Sebti
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

9.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

Authors:  Michael Hedvat; Dennis Huszar; Andreas Herrmann; Joseph M Gozgit; Anne Schroeder; Adam Sheehy; Ralf Buettner; David Proia; Claudia M Kowolik; Hong Xin; Brian Armstrong; Geraldine Bebernitz; Shaobu Weng; Lin Wang; Minwei Ye; Kristen McEachern; Huawei Chen; Deborah Morosini; Kirsten Bell; Marat Alimzhanov; Stephanos Ioannidis; Patricia McCoon; Zhu A Cao; Hua Yu; Richard Jove; Michael Zinda
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

Review 10.  A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation.

Authors:  Erik A Nelson; Sreenath V Sharma; Jeffrey Settleman; David A Frank
Journal:  Oncotarget       Date:  2011-06
View more
  42 in total

1.  Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Filippo Prencipe; Carlota Lopez-Cara; Riccardo Rondanin; Daniele Simoni; Ernest Hamel; Stefania Grimaudo; Rosaria Maria Pipitone; Maria Meli; Manlio Tolomeo
Journal:  Eur J Med Chem       Date:  2015-11-27       Impact factor: 6.514

2.  Adaptor proteins NUMB and NUMBL promote cell cycle withdrawal by targeting ERBB2 for degradation.

Authors:  Maretoshi Hirai; Yoh Arita; C Jane McGlade; Kuo-Fen Lee; Ju Chen; Sylvia M Evans
Journal:  J Clin Invest       Date:  2017-01-09       Impact factor: 14.808

3.  p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.

Authors:  Amir Sonnenblick; Roberto Salgado; Sylvain Brohée; Tamar Zahavi; Tamar Peretz; Gert Van den Eynden; Ghizlane Rouas; Asher Salmon; Prudence A Francis; Angelo Di Leo; John P A Crown; Giuseppe Viale; Laura Daly; Bahar Javdan; Sho Fujisawa; Evandro De Azambuja; Ameye Lieveke; Martine J Piccart; Jacqueline F Bromberg; Christos Sotiriou
Journal:  Int J Oncol       Date:  2017-11-27       Impact factor: 5.650

Review 4.  Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis.

Authors:  Etty N Benveniste; Yudong Liu; Braden C McFarland; Hongwei Qin
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

5.  Genetic variation in the JAK/STAT/SOCS signaling pathway influences breast cancer-specific mortality through interaction with cigarette smoking and use of aspirin/NSAIDs: the Breast Cancer Health Disparities Study.

Authors:  Martha L Slattery; Abbie Lundgreen; Lisa M Hines; Gabriela Torres-Mejia; Roger K Wolff; Mariana C Stern; Esther M John
Journal:  Breast Cancer Res Treat       Date:  2014-08-08       Impact factor: 4.872

Review 6.  Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors.

Authors:  Lisa N Heppler; David A Frank
Journal:  Trends Cancer       Date:  2017-11-10

7.  FYN promotes mesenchymal phenotypes of basal type breast cancer cells through STAT5/NOTCH2 signaling node.

Authors:  Ga-Hang Lee; Ki-Chun Yoo; Yoojeong An; Hae-June Lee; Minyoung Lee; Nizam Uddin; Min-Jung Kim; In-Gyu Kim; Yongjoon Suh; Su-Jae Lee
Journal:  Oncogene       Date:  2018-01-19       Impact factor: 9.867

Review 8.  Constitutive activation of STAT3 in breast cancer cells: A review.

Authors:  Kasturi Banerjee; Haluk Resat
Journal:  Int J Cancer       Date:  2015-11-28       Impact factor: 7.396

9.  Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.

Authors:  Chun-Yu Liu; Kuen-Feng Chen; Tzu-I Chao; Pei-Yi Chu; Chun-Teng Huang; Tzu-Ting Huang; Hsiu-Ping Yang; Wan-Lun Wang; Chia-Han Lee; Ka-Yi Lau; Wen-Chun Tsai; Jung-Chen Su; Chia-Yun Wu; Ming-Huang Chen; Chung-Wai Shiau; Ling-Ming Tseng
Journal:  J Mol Med (Berl)       Date:  2017-06-04       Impact factor: 4.599

10.  Ligand-induced STAT3 signaling increases at relapse and is associated with outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  Alexandra M Stevens; Marcos J Ruiz; Robert B Gerbing; Todd A Alonzo; Alan S Gamis; Michele S Redell
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.